Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumorsThomas J. Semrad, Karen Kelly, I-Yeh Gong et al.|Cancer Chemotherapy and Pharmacology|2021Cited by 12